Research programme: PRC 1 small molecule inhibitor - Johnson & Johnson Innovative Medicine
Alternative Names: polycomb repressive complex 1 inhibitors - Johnson & Johnson Innovative MedicineLatest Information Update: 10 Oct 2023
Price :
$50 *
At a glance
- Originator Janssen Pharmaceuticals
- Developer Johnson & Johnson Innovative Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Leukaemia
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 14 Apr 2023 Preclinical trials in Leukaemia in Belgium (unspecified route) before April 2023
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in Leukemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)